A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

BACKGROUND: Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients with SCD, we conducted a double-blind, randomized, place...

Descripción completa

Detalles Bibliográficos
Autores principales: Wun, Ted, Soulieres, Denis, Frelinger, Andrew L, Krishnamurti, Lakshmanan, Novelli, Enrico M, Kutlar, Abdullah, Ataga, Kenneth I, Knupp, Charles L, McMahon, Lillian E, Strouse, John J, Zhou, Chunmei, Heath, Lori E, Nwachuku, Chuke E, Jakubowski, Joseph A, Riesmeyer, Jeffrey S, Winters, Kenneth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585853/
https://www.ncbi.nlm.nih.gov/pubmed/23414938
http://dx.doi.org/10.1186/1756-8722-6-17

Ejemplares similares

Ejemplares similares